Versiti, a company involved in blood health innovation, acquired Pearl Pathways, an advisor and partner for enabling innovative and expedited life science product development.

Indianapolis-based Pearl Pathways is a full-service life science consulting firm, providing regulatory affairs, quality compliance, and niche CRO services. Pearl also has an independent, AHRPP accredited IRB supporting all aspects of human research. The organization supports biopharmaceutical, medical device, and diagnostic companies, as well as life science service providers with comprehensive clinical, regulatory, and quality compliance needs.

Pearl Pathways allows Versiti to serve clinical trials sponsors earlier and with more depth in the development pathway while continuing to provide services through regulatory approval and commercialization.

Adding to capabilities developed through Versiti’s Diagnostic Laboratories, the transaction follows the organization’s acquisition earlier this year of Quantigen, a specialty laboratory based in Fishers, Indiana, and the Texas-based Cenetron Central Laboratories and Salus IRB in 2019. 

“Pearl Pathways brings deep expertise in life science product development, which ultimately leads to getting life-saving devices, diagnostics, and therapeutics to patients faster,” said Versiti President and CEO Chris Miskel. “This strategic collaboration not only enriches the scope and diversity of our research-based solutions from Versiti Clinical Trials, but also bolsters our spectrum of capabilities to support curing diseases sooner.”